38
The
th Annual Meeting of April 8-9, 2017 The Endocrine Society and The Diabetes Association of the R.O.C. (Taiwan)
OE-01
PROTEOMIC ANALYSIS OF ANAPLASTIC THYROID CANCER CELLDERIVED EXOSOME FOR TUMOR THERAPY VIA LOVASTATININDUCED DIFFERENTIATION AND VILDAGLIPTIN-INHIBITED DIPEPTIDYL PEPTIDASE-IV (DPP-IV) ACTIVITY 1
CHIH-YUAN WANG, 2HAO-AI SHUI, 2TIEN-CHUN CHANG
1
Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University,Taipei, Taiwan; 2Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan
Anaplastic or undifferentiated carcinoma cells proliferate rapidly and are easy to metastasize. Our UHVXOWV KDYH RYHUWXUQHG WKH QRWLRQ WKDW ORYDVWDWLQ LV EHQH¿FLDO WR FDQFHU WKHUDS\ DQG VXJJHVWHG WKDW the effect of Lovastatin on the undifferentiated thyroid carcinoma with the concentration of the dose is double-edged. In addition to Lovastation, inhibitors of Dipeptidyl peptidase-4 (DPP4, or CD26) may KDYH D VLJQL¿FDQW HIIHFW RQ FDQFHU ZLWK SULPDU\ HYLGHQFH IURP VHYHUDO UHSRUWV VXJJHVWLQJ WKDW '33 is involved in the proliferation and metastasis of prostate cancer cells and that DPP4 can promote or inhibit cancer cells by regulating their receptors, such as growth factors, chemokines, neuropeptides, and vasoactive peptides. In the study of prostate cancer also found that, DPP4 through the regulation of intracellular mitogenic peptide (mitogenic peptides) activity, thereby affecting the development of cancer. Vildagliptin is an inhibitor of DPP4 and belongs to the class of pancreatic islet enhancers. It is a potent and selective inhibitor of DPP4 activity and has been shown to promote the growth of intestinal cancer cells. Whether the drugs affect the growth of undifferentiated thyroid cancer cells is still unclear. It is now known that cancer cells tend to increase the survival rate of cancer cells through the expression of heat shock proteins (HSPs) to protect against environmental stress and to treat cancer drugs, or to regulate the proliferation of cancer cells via the mTOR signaling pathway. As described in the previous studies, both Lovastatin and Vildagliptin have an effect on cancer cell development, but whether these two drugs through the HSP and mTOR for thyroid anaplastic carcinoma or thyroid follicular carcinoma of the tumor cells is still unclear. In addition, HSP is also one of the biomarkers of the exosome surface of cancer cells. In clinical applications, exosomal proteins are considered to have the potential to predict the diagnosis, treatment and biomarker of health and disease. , Exosomes have WKH UROH RI FHOO WR FHOO FRPPXQLFDWLRQ DQG VPDOO PROHFXOH WUDQVSRUW DQG FDQ LQÀXHQFH FHOO JURZWK After several tests, the results showed that ARO cells expressed DPP4 protein, and adding 1uM Vildagliptin and 25uM Lovastatin treatment of ARO cells and SW579 cells, found that Vildagliptin $52 FHOOV ZLOO PDNH WKH '33 SURWHLQ SHUIRUPDQFH GHFUHDVHG ,Q DGGLWLRQ WR FRQ¿UPLQJ WKDW $52 FHOOV GLG LQGHHG H[SUHVV '33 SURWHLQ LW ZDV DOVR FRQ¿UPHG WKDW 9LOGDJOLSWLQ GLG LQKLELW '33 SURWHLQ expression. 112
